Patent US1788962A successfully refreshed from Google Patents.
EP0169787B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of oligonucleotides bonded to an intercalating agent as drugs
Assignee: Centre National de la Recherche Scientifique
•
Filing: 1985-07-22
•
Granted: 1989-09-06
•
Expires: 2005-07-22
Abstract
Abstract 1. Claims for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE Drugs, in the form of oligonucleotide compounds bonded to an intercalating agent and comprising an oligonucleotide or an oligodesoxynucleotide made up of a chain of natural or modified nucleotides and complementary with a nucleic acid sequence to which an intercalating group is attached by a covalent bond, the nucleic acid sequence constituting all or part of a sequence involved in initiation, propagation or termination of the replication of a nucleic acid and of transcription and/or translation of one or more genes. 1. Claims for the Contracting State : AT A method of manufacturing drugs comprising oligonucleotide compounds bonded to an intercalating agent consisting of an oligonucleotide or oligodesoxynucleotide made up of a chain of natural or modified nucleotides complementary with a nucleic acid sequence, characterised in that an intercalating group is attached by a covalent bond to the aforementioned nucleic acid sequence which constitutes all or part of a sequence involved in initiation, propagation or termination of replication of a nucleic acid, and of transcription and/or translation of one or more genes.
Inventors
- 👤 Claude Helene
- 👤 Thanh Thuong Nguyen
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 00:37
CPC Classifications
C; C07; C07H; C07H21/00; A; A61; A61P; A61P31/00; A61P31/04; A61P31/12; A61P33/00; A61P33/10; A61P35/00
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
81 words
Drugs, in the form of oligonucleotide compounds bonded to an intercalating agent and comprising an oligonucleotide or an oligodesoxynucleotide made up of a chain of natural or modified nucleotides and complementary with a nucleic acid sequence to which an intercalating group is attached by a covalent bond, the nucleic acid sequence constituting all or part of a sequence involved in initiation, propagation or termination of the replication of a nucleic acid and of transcription and/or translation of one or more genes.
Claim 2
Dependent Claim
81 words
Drugs, in the form of oligonucleotide compounds bonded to an intercalating agent and comprising an oligonucleotide or an oligodesoxynucleotide made up of a chain of natural or modified nucleotides and complementary with a nucleic acid sequence to which an intercalating group is attached by a covalent bond, the nucleic acid sequence constituting all or part of a sequence involved in initiation, propagation or termination of the replication of a nucleic acid and of transcription and/or translation of one or more genes.
Claim 3
Dependent Claim
32 words
Drugs according to claim 1, in the form of compounds characterised in that the oligonucleotide or oligodesoxynucleotide is complementary with a sequence for replicating or developing a virus or bacterium or parasite.
Claim 4
Dependent Claim
31 words
Drugs according to claim 2, in the form of compounds characterised in that the sequence of oligonucleotides or oligodesoxynucleotides is complementary with a region for regulation, initiation or propagation of replication.
Claim 5
Dependent Claim
45 words
Drugs according to claim 1, in the form of compounds characterised in that the sequence of oligonucleotides or oligodesoxynucleotides is complementary with a nucleic acid sequence for expressing a gene which codes for a factor giving resistance to antibiotics or antiviral agents or antiparasitic agents.
Claim 6
Dependent Claim
25 words
Drugs according to claim 2 or 3, in the form of compounds characterised in that the virus is the influenza virus or the herpes virus.
Claim 7
Dependent Claim
31 words
Drugs according to claim 1, in the form of compounds characterised in that the sequence of oligonucleotides or oligodesoxynucleotides is complementary with a nucleic acid sequence for expressing an oncogenic gene.
Claim 8
Dependent Claim
186 words
Drugs according to any of claims 1 to 6, in the form of compounds having the formula: in which: the radicals B can be identical or different and each denote a natural or modified nucleic acid base, the radicals X, which can be identical or different, each represent an oxoanion O ⊖ or a thioanion S 9 or an alkyl group or an alkoxy, aryloxy, alkoxy or alkyl group substituted by a nitrogen-containing heterocycle, or an aminoalkyl group or an aminoalkoxy group or a thioalkyl group or a -Y-Z group; R and R', which can be identical or different, each represent a hydrogen atom or a -Y-Z group in which: Y represents a straight-chain or branched alkylene radical -alk- or a radical in which E can have the same meanings as X except Y-Z; or a radical -Y"-0-Y' where Y" and Y' can have the meanings given for Y, Z is a radical corresponding to an intercalating agent; only one out of X, R and R' is a Y-Z group; J represents a hydrogen atom or a hydroxy group, and n is an integer including O.
Claim 9
Dependent Claim
27 words
Drugs according to claim 7, in the form of compounds characterised in that the intercalating agent Z is chosen from among polycyclic compounds having a plane configuration.
Claim 10
Dependent Claim
22 words
Drugs according to claim 8, in the form of compounds characterised in that Z is chosen from among acridine, furocoumarin or ellipticine.
Claim 11
Dependent Claim
86 words
Drugs according to any of claims 1 to 9, in the form of compounds characterised in that the radical B is a radical corresponding to thymine, adenine, 2-aminoadenine and derivatives thereof substituted e.g. on the N 6 by an aminoalkylene group or by an azidophenylalkylene group, cytosine, guanine or guanine substituted on the 0 6 e.g. by an (ω-alkylene)-9-acridine group, or 8-(ω-aminoalkyl)-aminoadenine and derivatives thereof substituted on the NH 2 at ω by an acridine group; uracil, 5-bromo-uracil, 8-azidoadenine or a photoactivatable derivative of the bases.
Claim 12
Dependent Claim
24 words
Drugs according to any of claims 1 to 10, in the form of compounds characterised in that the radical Z is chosen from among:
Claim 13
Dependent Claim
47 words
Drugs according to any of claims 1 to 11, in the form of compounds characterised in that B is chosen from among T, G, A, C and U; X is chosen from among O - , methyl, ethyl, propyl, methoxy, ethoxy and propoxy, and J = H.
Claim 14
Dependent Claim
26 words
Drugs according to claim 1, in the form of compounds characterised in that the compounds are chosen from among: in which Z is an intercalating agent.
Claim 15
Dependent Claim
28 words
A pharmaceutical composition characterised in that the active principle therein is at least one drug according to any of claims 1 to 13 and a pharmaceutically acceptable excipient.
Claim 16
Dependent Claim
25 words
A pharmaceutical composition according to claim 14, characterised in that it also comprises an antibiotic, an antiparasitic agent, an antiviral agent or an antitumor agent.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.